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ng author. Tel.: +32 16
ess: steven.simoens@phSummary This article synthesizes and appraises the methodological quality of the
international literature on costs of chronic obstructive pulmonary disease (COPD)
exacerbations, economic value of antimicrobial therapy of exacerbations, and
factors affecting the economic value of antibiotics. Included studies had carried out
a cost-of-illness, cost–effectiveness, cost–utility or cost–benefit analysis. Exacerba-
tion costs varied between countries and increased with the severity of the
exacerbation. Hospitalization costs accounted for more than 45% of healthcare
costs of exacerbations. Drug costs made up 6–21% of healthcare costs in the majority
of studies. Cost estimates were biased due to difficulties involved in diagnosing and
treating exacerbations, and because the patient sample studied may not be
representative of the population of patients suffering from exacerbations. Although
this needs to be corroborated by future research, evidence is emerging that second-
generation antibiotics such as fluoroquinolones may have a favourable economic
profile as compared with first-generation antibiotics. The higher acquisition costs of
fluoroquinolones appear to be balanced by less treatment failure, more time
between exacerbation episodes, and lower hospitalization costs. There is a need for
prospective economic evaluations alongside clinical trials with a sufficient number of
patients and length of follow-up period. The economic value of antibiotics is
influenced by difficulties involved in diagnosing the condition, effectiveness,
resistance, patient compliance with treatment, and treatment failure associated
with antibiotics. The small number of economic evaluations and their methodolo-
gical limitations precludes the recommendation of a specific antibiotic for use in the
management of COPD exacerbations on economic grounds.
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Chronic obstructive pulmonary disease (COPD) is a
disease characterized by chronic airflow limitation
which is not fully reversible, progressive and linked
with an abnormal inflammatory response to noxious
stimuli.1 The decline in lung function of COPD
patients tends to be accompanied by intermittent
acute exacerbations. Although there is debate
about the exact definition of a COPD exacerbation,
a well-accepted definition states that a COPD
exacerbation requires the presence of one or more
of the following clinical symptoms: increase in
sputum purulence, increase in sputum volume, and
worsening of dyspnea.2
COPD exacerbations are associated with signifi-
cant morbidity, impaired quality of life, mortality,
and are a primary driver of hospital admissions and
healthcare costs. Exacerbations worsen the natural
history of COPD and lead to poorer functional status
and quality of life.3 An inpatient mortality rate of
COPD exacerbations of 10%, rising to 40% in 1 year,
has been reported.4 The literature indicates that
3–16% of exacerbations give rise to a hospital
admission.3,5 A British study found that 10% of
hospital admissions in the UK originate from COPD
exacerbations.6 Half of hospitalized patients need
to be re-admitted to hospital at least once in the
next 6 months.7 Exacerbations make up around 70%
of direct healthcare costs of COPD.8
COPD exacerbations are generally triggered by
respiratory infections, but also by environmental
exposures (e.g. air pollutants, dust) and co-morbidities
(e.g. heart failure, pulmonary embolism, pneu-
mothorax and non-pulmonary infections). Forty to
fifty per cent of respiratory infections are caused
by bacteria, with the most common bacterial
isolates being Haemophilus influenzae, Streptococ-cus pneumoniae, and Moraxella catarrhalis. Other
causes of respiratory infections are viruses (30%)
and atypical bacteria (5–10%).9 Although there
is some controversy over the role of bacterial
infections, literature reviews and meta-analyses
have found that antibiotics improve clinical out-
comes in COPD exacerbations and that patients
with more severe exacerbations benefit more from
antibiotics.10–12
There is some debate about the choice of
antibiotic in the management of exacerbations.
Guidelines on the diagnosis, management and
prevention of COPD issued by the World Health
Organization Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) recommend that the
choice of antibiotic reflects local patterns of
microbial resistance to H. influenzae, S. pneumo-
niae, and M. catarrhalis.1 Increased resistance to
traditional first-generation antibiotics (aminopeni-
cillins, macrolides, tetracyclines) needs to be
weighed against higher acquisition costs and
relative effectiveness of cephalosporins, second-
generation macrolides and fluoroquinolones. Addi-
tionally, in selecting an antibiotic, a physician
needs to consider dose form, ease of administra-
tion, frequency of dosing, spectrum of activity,
duration of treatment, adverse effect profile and
potential drug interactions.
The aim of this article is to synthesize the
international literature on economic aspects of
antimicrobial therapy of acute exacerbations of
COPD. This review focuses on three specific
aspects: first, the level and distribution of costs
associated with exacerbations; second, the eco-
nomic value of antibiotics in the management of
COPD exacerbations; and third, factors influencing
the economic value of antibiotics. Methodological
issues surrounding the evaluation of costs and
ARTICLE IN PRESS
Antimicrobial use in acute exacerbations of COPD 17economic value of antibiotics are also explored.
The relevance of the findings is discussed and gaps
in the evidence base are identified.Methods
Search strategy
Studies were identified by searching the following
electronic databases up to December 2005:
PubMed, EMBASE, Bath Information and Data
Services, National Health Service Economic Evalua-
tion Database, Cochrane Library, EconLit, and
Social Science and Citation Index. Search terms
included ‘COPD’, ‘chronic bronchitis (CB)’, ‘em-
physema’, ‘acute exacerbation’, ‘costs’, ‘costs of
treatment’, ‘cost-of-illness’, ‘pharmaco-econom-
ics’, ‘economic evaluation’, ‘cost–effectiveness’,
‘cost–minimization’, ‘cost–utility’, ‘cost–benefit’
alone and in combination with each other. Addi-
tionally, the bibliography of included studies was
checked for other relevant studies.Economic techniques
Information about the costs of COPD exacerbations
was derived from cost-of-illness analyses. A cost-
of-illness analysis was defined as a study quantify-
ing the costs involved in treating an exacerbation.
The economic value of antimicrobial therapy was
derived from cost–effectiveness, cost–utility and
cost–benefit analyses. Cost–effectiveness analysis
denotes an economic evaluation where a single
consequence is quantified in a natural unit, such as
the number of successfully treated patients, the
number of exacerbation-symptom days averted or
the number of patients without recurrence of
exacerbation. The incremental cost–effectiveness
ratio is calculated as the difference in costs
between alternatives divided by the difference
in the consequence. This technique is of less
value when multiple consequences need to be
considered.
A study that measures consequences by specific
health-related quality of life measures, such as
quality-adjusted life years (QALYs), is referred to as
a cost–utility analysis. The QALY takes into account
the quantity and quality of life. Quality of life
associated with a health state is measured on a
scale of 0 (reflecting death) to 1 (reflecting perfect
health). Quality of life data are then combined with
estimates of the time period for which the health
benefits last to generate QALYs.Cost–benefit analysis refers to an economic
evaluation where consequences are valued in
monetary terms. A monetary value can be assigned
to health benefits by means of, for instance, the
willingness-to-pay technique. As a result, benefits
can be compared with costs of antimicrobial
therapy and the net worth (benefits minus costs)
of each of the treatment alternatives can be
estimated. The results of a cost–benefit analysis
may be stated in the form of the net benefit or loss
of one alternative over another or in the form of a
ratio of benefits to costs.
Data analysis
To compare costs between studies, costs were
actualized to 2001 values using a rate of inflation
based on the evolution of the Consumer Price
Index. Costs were converted using US dollar
exchange rates.
Assessment of methodological quality
A qualitative appraisal was carried out of the
methodological quality of cost-of-illness studies
by investigating study population, data sources,
methods of data collection, scope of included costs
and time horizon. The quality of economic evalua-
tions was assessed by considering the perspective,
scope and measurement of costs and conse-
quences, sources of data on costs and conse-
quences, and application of an incremental
analysis.13Results
Cost-of-illness studies of COPD exacerbations
The literature search generated 52 articles. Arti-
cles were excluded if healthcare resource utiliza-
tion was not converted into costs or if costs of
exacerbations were not distinguished from costs of
underlying COPD or co-morbidities. Nine cost-of-
illness studies of COPD exacerbations were included
in the review.5,14–21
Direct healthcare costs of drugs, contacts with
healthcare professionals and hospitalization vary
substantially from study to study, with estimates
ranging from $123 to $666 per exacerbation (see
Table 1).5,15,18,20 This variation in cost estimates
originates, amongst other things, from differences
between countries in healthcare resource utiliza-
tion, prices, clinical practice, the organization and
funding of healthcare systems. One study explored
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Table 2 Distribution of direct healthcare costs of COPD exacerbations.
Country Hospitalisation costs (%) Drug costs (%) Other outpatient costs (%) Reference
USA 97 0.4 2 14
Netherlands/Belgium 79 8 14 20
Italy 77 10 14 21
Sweden 69 6 25 18
Spain 67 21 11 5
UK 44 11 45 16
Germany 44 34 22 15
Table 1 Direct healthcare costs per COPD exacerbation.
Country Costs per exacerbation ($) Reference
Spain 123 5
Germany 146 15
Sweden 334 18
Netherlands/Belgium 666 20
Argentina, Brazil, Colombia, Ecuador, Mexico, Peru, Venezuela 98–329 19
S. Simoens et al.18the sensitivity of costs to differences in prices
between countries.19 Costs of treating an exacer-
bation were compared between Argentina, Brazil,
Colombia, Ecuador, Mexico, Peru and Venezuela.
The authors derived data on healthcare resource
utilization from a Spanish study.5 These data were
then combined with price information for each
country to calculate costs. The analysis revealed
that costs per exacerbation ranged from $98 in
Colombia to $329 in Argentina.
Direct healthcare costs increase with the severity
of the exacerbation. A Swedish study defined
severity on the basis of healthcare resource use.18
Costs per exacerbation amounted to $13 for a mild
exacerbation; $226 for a moderate exacerbation;
and $2330 for a severe exacerbation. The authors
of a Dutch/Belgian study defined exacerbation
severity in terms of a physician assessment of the
impact of the exacerbation on ability to perform
usual activities.20 Costs per exacerbation amounted
to $81 for a mild exacerbation; $532 for a moderate
exacerbation; and $3719 for a severe exacerbation.
The distribution of direct healthcare costs of
exacerbations is presented in Table 2. The principal
cost driver of direct healthcare costs is inpatient
costs, accounting for more than 45% of direct
healthcare costs. As hospitalization is generally
indicative of treatment failure, these estimates
highlight the potential savings that can be attained
from preventing treatment failure. One study
focused specifically on quantifying costs of treat-ment failure. Costs of treatment failure arising
from additional outpatient visits, emergency de-
partment visits and hospitalizations accounted for
29–63% of direct healthcare costs, depending on
the country.19 Table 2 also shows that the second
most important cost driver of direct healthcare
costs tends to be other outpatient costs arising
from contacts with healthcare professionals and
diagnostic tests (2–45%). Drug costs cover up to 35%
of direct healthcare costs, with the majority of
studies having estimates between 6% and 21%.
Few studies have quantified direct non-health-
care costs of transportation to healthcare profes-
sionals associated with treatment of exacerbations.
A Swedish and a Dutch/Belgian study found similar
estimates indicating that transportation costs
account for less than 3% of direct costs.18,20 No
study explored direct non-healthcare costs asso-
ciated with home adaptations and educational
requirements.
The few available estimates of indirect costs of
productivity loss associated with exacerbations
vary, depending on the scope of costs included.
An Italian cost-of-illness study investigated indirect
costs arising from work absenteeism of patients
during treatment of exacerbations.21 The authors
found that indirect costs made up 3% of annual
costs per patient. A German study not only
considered work absenteeism, but also took into
account productivity loss arising from premature
death of patients and productivity loss of family/
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accounted for 47% of costs per exacerbation.Quality of cost-of-illness studies of COPD
exacerbations
Some cost-of-illness studies enrolled national sam-
ples that are representative of the popula-
tion,14,16,17 whereas others analyzed a specific
group of patients.5,15,18–21 Differences in, for
example, age and disease severity of the study
population influence cost estimates. With respect
to age of patients, a US study observed that costs of
patients aged 65 years and over were around three
times higher than costs of patients aged under 65
years.14 With respect to disease severity, two
studies found that costs per exacerbation were
7–10 times higher for a severe exacerbation than
for a moderate exacerbation.18,20
A combination of survey and claims data were
used in studies to obtain information about health
resource utilization associated with exacerbations.
The reliability of survey data is hindered by
patients’ ability to recall health resource utiliza-
tion. Claims data may suffer from missing data and
incorrect diagnostic coding of claims. Examining
the impact of the data source on cost estimates, a
US study found that hospitalization costs per
discharge amounted to $6336; $6677 or $7038,
depending on the data source used.17 Studies
enrolling a specific group of patients tend to be
carried out prospectively using survey
data.5,15,18–21 This type of analysis can be consid-
ered to be more reliable than studies focusing on a
national sample, which are generally based on a
retrospective analysis of clinical databases.14,16,17
All but one cost-of-illness study identified pa-
tients suffering from exacerbations, but did not
have a control group of patients without exacer-
bations. Such case series analyses that focus on
identified patients only may be misleading in the
case of COPD exacerbations, where diagnosis is
complex and attribution of healthcare resource
utilization to the disease is difficult. A case–control
approach seems better suited in that it is more
inclusive and allows identification of additional
healthcare resource use related to exacerbations.
This approach was taken by one study which
compares patients suffering from CB exacerbations
with equivalent healthy patients.16
The scope of included costs was generally
restricted to direct healthcare costs associated
with exacerbations. This refers to costs of drugs,
contacts with healthcare professionals and hospi-
talization. Few studies have considered direct non-healthcare costs associated with transportation to
the healthcare professional,18,20 or indirect costs
arising from lost productivity of patients.15,21 The
omission of indirect costs is of minor concern given
that the population of patients that experience
COPD exacerbations tends to be elderly. Moreover,
in this population of elderly and frail patients, it is
not straightforward to distinguish lost productivity
of caregivers related to COPD exacerbations from
lost productivity related to general illness. Never-
theless, in order to gain an insight into the costs of
exacerbations from a societal perspective, future
studies need to collect data on all relevant costs
generated by patients suffering from exacerba-
tions.
Cost-of-illness studies measured costs of exacer-
bations during a certain time period. In studies that
reported on patients during 1 month, the duration
of the period may have been too short to capture
all relevant costs.5,19 Other studies had a longer
follow-up period of up to 6 months, but this period
was still too short to account for seasonal variations
in the frequency of exacerbations.18,21 Such studies
thus produced biased estimates of the burden of
illness associated with COPD exacerbations.Economic evaluations of antimicrobial
therapy of COPD exacerbations
A total of 57 articles were identified by the
literature search. Articles were excluded from the
review for the following reasons: treatment of
COPD rather than exacerbations, treatment not
involving antibiotics, analysis of a single interven-
tion without a comparator, absence of data on both
costs and consequences. The economic literature
evaluating antimicrobial therapy of COPD exacer-
bations consisted of seven cost–effectiveness ana-
lyses.22–28 Two studies examined both
cost–effectiveness and cost–utility.29,30 No cost–-
benefit analyses were identified. Characteristics of
these studies are reported in Table 3.
Three studies set in different countries con-
trasted the cost–effectiveness of aminopenicillins,
cephalosporins, macrolides and fluoroquinolones in
terms of the cost per successfully treated pa-
tient.22–24 These studies employed simple decision
analytic models populated with effectiveness data
derived from the literature and expert opinion. Two
analyses calculated average cost–effectiveness
ratios. An Italian study found comparable costs
per successfully treated COPD patient for first-line
therapy with co-amoxiclav and rufloxacin, which
tended to be more cost–effective than ciproflox-
acin and clarithromycin.23 Irrespective of severity
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S. Simoens et al.22of disease, a German study noted that ciprofloxacin
and cephalosporins were more cost–effective than
macrolides (roxithromycin, clarithromycin) and
aminopenicillins (amoxicillin, co-amoxiclav) in
treating CB exacerbations.24 A British study ex-
plored the incremental cost–effectiveness of two
courses of therapy with amoxicillin, co-amoxiclav,
cefaclor or ciprofloxacin in patients with severe CB
exacerbations.22 The findings showed that co-
amoxiclav as first-line and second-line therapy
dominated two courses of amoxicillin. The incre-
mental cost–effectiveness of amoxicillin followed
by co-amoxiclav, two courses of ciprofloxacin, and
amoxicillin followed by ciprofloxacin was $137,
$705 and $328 per successfully treated patient,
respectively.
A prospective analysis of 1097 Spanish patients
compared treatment of COPD exacerbations with
moxifloxacin (39% of patients), co-amoxiclav (32%)
or clarithromycin (29%) during 7–10 days.28 The
results indicated that costs of treatment failure
accounted for 44% of costs per exacerbation. This
percentage lies within the range of estimates
observed in the cost-of-illness literature.5,14–16,20,21
Moxifloxacin and co-amoxiclav had a similar cost
per exacerbation, but resolution of symptoms at 10
days occurred in a higher percentage of patients
treated with moxifloxacin. Costs and consequence
data were not combined into cost–effectiveness
ratios.
When contrasting the cost–effectiveness of dif-
ferent generations of antibiotics, higher drug
acquisition costs of newer antibiotics need to be
balanced against the relative effectiveness of
antibiotics, as this has implications for treatment
failure, time between exacerbation episodes,
hospitalization costs, and costs of lost productivity.
Two economic evaluations reviewed medical re-
cords of small samples of US patients suffering from
CB exacerbations who were not randomized to
antimicrobial therapy. Although the classification of
the different generations of antibiotics varied
between studies, one study found that newer
antibiotics (fluoroquinolones, azithromycin) were
associated with a lower failure rate and need for
hospitalization, more time between exacerbation
episodes, and a lower cost for treating exacerba-
tions.25 The second study found no significant
differences between groups of antimicrobial agents
in terms of costs or effectiveness.26
An economic evaluation examined treatment of
CB exacerbations with gemifloxacin, a fluoroquino-
lone, or with clarithromycin, a macrolide, in a
sample of US patients.27 Effectiveness was defined
as the percentage of patients without recurrence of
exacerbation requiring antimicrobial therapy after26 weeks. Costs were calculated from the perspec-
tive of the third-party payer (direct healthcare
costs) and the societal perspective (direct health-
care costs and costs arising from lost productivity).
Treatment with gemifloxacin was associated with
lower direct healthcare costs, inferior costs of lost
productivity, and a higher percentage of patients
without exacerbation recurrence. The authors
accounted for uncertainty around the point esti-
mates of incremental cost–effectiveness ratios and
calculated that the probability of gemifloxacin
dominating clarithromycin was 88% from the
perspective of the third-party payer and 84% from
the societal perspective.
Investigating cost–effectiveness as well as cos-
t–utility, two studies performed an economic
evaluation alongside the same randomized con-
trolled trial of Canadian patients that underwent
therapy of CB exacerbations with ciprofloxacin or
standard antibiotic care (amoxicillin, cefuroxime,
erythromycin, cefaclor and others).29,30 Incremen-
tal costs per exacerbation-symptom day averted
with ciprofloxacin as compared with standard care
were $232 from the perspective of the third-party
payer and $160 from the societal perspective.
Incremental costs per QALY gained with ciproflox-
acin were $20,644 and $14,199; respectively.Quality of economic evaluations of
antimicrobial therapy of COPD exacerbations
The perspective taken in economic evaluations was
that of the third-party payer24–26,28 or the National
Health Service.22,23 These studies considered direct
healthcare costs associated with treating exacer-
bations. On the one hand, this is acceptable as
interest in managing exacerbations tends to focus
on the type of antibiotics, intensity and length of
treatment in outpatient and inpatient settings. On
the other hand, such a perspective is too restrictive
as treatment has wider implications on employ-
ment of patients and family and friends who give
care to patients. Only three out of the eight
economic evaluations adopted a societal perspec-
tive.27,29,30
There was no uniformity in how consequences
were quantified. Some studies used intermediate
process measures (e.g. treatment compliance,
failure rate after first-line treatment),25,26,28 whilst
others opted for final measures (e.g. the number of
exacerbation-symptom days averted or the number
of patients without recurrence of exacerba-
tion).22–24,27,29,30
Economic evaluations were carried out alongside
randomized controlled trials27,29,30 or observational
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reflect real-world practices in managing patients
suffering from exacerbations. Investigating the
economic profile of treatment alternatives in a
trial setting provides a degree of internal validity.
This contrasts with the observational studies which
may be subject to selection bias.
Some studies employed simple decision analytic
models based on expert opinion and secondary data
taken from the literature.22–24 Capturing the
opinion of experts is a valid technique in the
absence of comparative trial results, although
empirical confirmation of assumptions used in the
model is needed. It should also be noted that many
of the primary studies used in modelling studies
were uncontrolled, enrolled a small sample, and
clinical data used were quite old. Therefore, more
attention needs to be paid to the study design and
quality of data. Further work is required to
standardize methods used in modelling studies.
It was possible to determine the economic value
of antimicrobial therapy in the four studies which
performed an incremental analysis.22,27,29,30 Two
studies computed average cost–effectiveness.23,24
Insight into the economic value of an antibiotic
requires that the additional costs and effectiveness
of the antibiotic as compared with the best,
currently used alternative is calculated. This
necessitates the calculation of incremental rather
than average cost–effectiveness ratios. Finally,
three studies measured multiple consequences
(so-called ‘‘cost–consequence analysis’’), and
did not combine costs and consequences into
cost–effectiveness ratios.25,26,28Factors affecting the economic value of
antimicrobial therapy of COPD
exacerbations
The economic value of antimicrobial therapy of
COPD exacerbations is influenced by a number of
factors including diagnosis, effectiveness, antimi-
crobial resistance, patient compliance with treat-
ment, and treatment failure.
Diagnosing a bacterial exacerbation is rendered
difficult by the fact that the diagnosis is generally
based on patients’ self-reported clinical symptoms
and high-quality sputum specimens are not always
available.1 This implies that antibiotics may be
prescribed to treat exacerbations that are not
bacterial in origin. A recent Belgian survey of
general practitioners and pulmonologists compared
actual management with GOLD recommenda-
tions.31 The authors concluded that antibioticswere overused in the treatment of COPD exacer-
bations and that their use should be limited to
those exacerbations where bacterial infection is
likely to be present. Inappropriate prescribing of
antibiotics is likely to have significant cost and
health consequences.32
The relative effectiveness of available antibiotics
plays a key role in determining the economic value
of antimicrobial therapy. Studies suggest that
second-generation macrolides and fluoroquinolones
are marginally more or equally effective as first-
generation antibiotics (aminopenicillins, macro-
lides, tetracyclines).33,34 However, this literature
is limited by the fact that most trials are powered
to demonstrate equivalence rather than clinical
superiority; have enrolled small samples that are
not always representative of the patient popula-
tion; and do not control for concomitant therapy or
for co-morbidities. There is a need to investigate
whether second-generation macrolides and fluor-
oquinolones are more effective than first-genera-
tion antibiotics. Given that these drugs have higher
acquisition costs, their relative effectiveness will
determine whether or not they exhibit a superior
economic value than first-generation antibiotics.
Antimicrobial resistance compromises the effec-
tiveness and, thus, undermines the economic value
of antimicrobial therapy. Increased resistance of
the main respiratory pathogens H. influenzae, S.
pneumoniae, and M. catarrhalis to first-generation
antibiotics has been observed.35,36 Second-genera-
tion antibiotics such as fluoroquinolones exhibit low
resistance and a broad spectrum of activity.37 GOLD
guidelines recommend that the choice of antibiotic
takes account of local patterns of antimicrobial
sensitivity among bacterial pathogens.1
The success of therapy also depends on patient
compliance, with compliance being affected by the
frequency of dosing, duration of treatment, ad-
verse events, ease of administering drugs, ease of
packaging, and price.38 Only one economic evalua-
tion of antimicrobial therapy quantified patient
compliance: rates of compliance defined as intake
of at least 80% of prescribed dose varied between
76% and 83%.28 Various strategies to enhance
patient compliance with antimicrobial therapy in
respiratory tract infections have been proposed
such as patient education, once-daily dosing
schedules, a convenient and acceptable form of
medication, easy-to-open packaging, and the
choice of an antibiotic with few side effects.38
Antimicrobial resistance and poor patient com-
pliance need to be considered when choosing an
antibiotic because they may lead to treatment
failure and further antimicrobial therapy or hospi-
talization. Treatment failure may also be caused by
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that frequency of exacerbations, presence of co-
morbidities, impairment in lung function, need for
more aggressive bronchodilator therapy, and pre-
vious hospitalization predict treatment fail-
ure.12,39,40 The ability to identify patients at a
higher risk of failing treatment should aid clinicians
in their choice of antibiotic and inform decisions
about hospital admission.41Discussion
This literature review summarized evidence on
economic aspects of antimicrobial therapy of COPD
exacerbations. In light of the small number of
economic evaluations and methodological limita-
tions of these studies, it is not possible to
recommend an antibiotic for preferential use in
the management of COPD exacerbations on eco-
nomic grounds.
Defining an optimal strategy to manage COPD
exacerbations is difficult given that studies use
different definitions of an exacerbation. Although
variation in definitions may appear slight, such
differences matter when interpreting and compar-
ing results across studies. Symptom-based defini-
tions have been linked to therapeutic decisions,4
but may under-report exacerbations.3 Defining an
exacerbation in terms of healthcare resource use
recognizes that more severe exacerbations are
associated with higher resource use, but inhibits
international comparison because treatment pat-
terns and, thus, classification systems of exacerba-
tion severity vary across countries.
The cost-of-illness literature has demonstrated
that inpatient costs represent the principal com-
ponent of costs of treating COPD exacerbations.
This indicates that considerable savings can be
generated by more effective antibiotics that allow
patients to be managed in primary care and that
prevent treatment failure and hospitalization.
Acquisition costs of antimicrobial drugs make up a
limited percentage of treatment costs. However,
these cost estimates are biased given the difficul-
ties involved in correctly diagnosing and treating
patients suffering from exacerbations in daily
practice. Furthermore, estimates were derived
for specific patient samples and may not be
generalizable to the population of patients suffer-
ing from exacerbations.
Evidence is emerging that second-generation
antibiotics such as fluoroquinolones may have a
favourable economic profile as compared with first-
generation antibiotics. This seems to arise from the
fact that fluoroquinolones have higher acquisitioncosts, but are also associated with less treatment
failure, more time between exacerbation episodes,
and lower hospitalization costs. Fluoroquinolones
are likely to have a better economic profile in
countries where inpatient costs account for a higher
percentage of costs of managing exacerbations. If
corroborated by future research, there may be a
role for fluoroquinolones as a first-line treatment
for COPD exacerbations in the presence of increased
resistance to first-generation antibiotics or for
patients who are at increased risk of treatment
failure. The Canadian Thoracic Society and the
Canadian Infectious Disease Society recommend
fluoroquinolones as first-line treatment for patients
suffering from CB exacerbations who are at risk of
failing therapy with first-generation antibiotics such
as aminopenicillins, macrolides and tetracyclines.42
When comparing the economic value of different
generations of antibiotics, it is crucial that studies
have sufficient statistical power to explore the
impact of antibiotics on time between exacerba-
tions, treatment failure, outpatient and inpatient
costs. Studies not only need to enroll a sufficient
number of patients, but also need to follow up
these patients for a minimum period of time in
order to be able to detect potential differences in
these outcome parameters and in the economic
value of various antibiotics.
There is a need for more, better-designed and
comprehensive economic evaluations examining
the economic profile of antimicrobial therapy of
COPD exacerbations. Studies need to be carried out
that collect primary data on cost–effectiveness and
cost–utility. Analyses based on randomized con-
trolled trials provide a degree of internal validity,
while analyses based on cohort studies reflect real-
life practice.13 Alternatively, modelling approaches
can be employed based on high-quality data taken
from the literature. Moreover, to date, there have
been no cost–benefit analyses that balance costs of
antimicrobial therapy against the patient’s will-
ingness to pay to avoid exacerbations.Acknowledgements
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